+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Burns - Pipeline Review, H1 2020

  • ID: 4997656
  • Drug Pipelines
  • February 2020
  • Region: Global
  • 108 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • AlgiPharma AS
  • CFM Pharma Holding BV
  • FortuneRock (China) Ltd
  • Mallinckrodt Plc
  • Novion Technologies Inc
  • TreeFrog Therapeutics SAS
  • MORE
Burns - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Burns - Pipeline Review, H1 2020, provides an overview of the Burns (Dermatology) pipeline landscape.

A burn is damage to body's tissues caused by heat, chemicals, electricity, sunlight or radiation. Symptoms include pain, increasing with each degree of burn, red and swollen skin, blisters and charred and blackened skin. Treatment includes antibiotics and pain relievers.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Burns - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Burns (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Burns (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Burns and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 4, 1, 19, 4 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Burns (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Burns (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Burns (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Burns (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Burns (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Burns (Dermatology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Burns (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Burns (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AlgiPharma AS
  • CFM Pharma Holding BV
  • FortuneRock (China) Ltd
  • Mallinckrodt Plc
  • Novion Technologies Inc
  • TreeFrog Therapeutics SAS
  • MORE
Introduction
Burns - Overview
Burns - Therapeutics Development
Burns - Therapeutics Assessment
Burns - Companies Involved in Therapeutics Development
Burns - Drug Profiles
Burns - Dormant Projects
Burns - Discontinued Products
Burns - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Burns, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Burns - Pipeline by AlgiPharma AS, H1 2020
Burns - Pipeline by Alliance Pharma Plc, H1 2020
Burns - Pipeline by Anterogen Co Ltd, H1 2020
Burns - Pipeline by Bioharmony Therapeutics Inc, H1 2020
Burns - Pipeline by Biomendics LLC, H1 2020
Burns - Pipeline by CFM Pharma Holding BV, H1 2020
Burns - Pipeline by Chrysalis BioTherapeutics Inc, H1 2020
Burns - Pipeline by Combangio Inc, H1 2020
Burns - Pipeline by Destiny Pharma Plc, H1 2020
Burns - Pipeline by Energenesis Biomedical Co Ltd, H1 2020
Burns - Pipeline by FirstString Research Inc, H1 2020
Burns - Pipeline by FortuneRock (China) Ltd, H1 2020
Burns - Pipeline by GNT Pharma Co Ltd, H1 2020
Burns - Pipeline by Hunan Sanqing Pharmaceutical Co Ltd, H1 2020
Burns - Pipeline by Hypo-Stream Ltd, H1 2020
Burns - Pipeline by Madam Therapeutics BV, H1 2020
Burns - Pipeline by Mallinckrodt Plc, H1 2020
Burns - Pipeline by Marizyme Inc, H1 2020
Burns - Pipeline by MediWound Ltd, H1 2020
Burns - Pipeline by MicroCures Inc, H1 2020
Burns - Pipeline by NeoMatrix Therapeutics Inc, H1 2020
Burns - Pipeline by Novion Technologies Inc, H1 2020
Burns - Pipeline by Phagelux Inc, H1 2020
Burns - Pipeline by Riptide Bioscience Inc, H1 2020
Burns - Pipeline by Se-cure Pharmaceuticals Ltd, H1 2020
Burns - Pipeline by Shulov Innovative Science Ltd, H1 2020
Burns - Pipeline by Stemsynergy Therapeutics Inc, H1 2020
Burns - Pipeline by TGV-Inhalonix Inc, H1 2020
Burns - Pipeline by Theragnostic Technologies Inc, H1 2020
Burns - Pipeline by TreeFrog Therapeutics SAS, H1 2020
Burns - Pipeline by USV Pvt Ltd, H1 2020
Burns - Pipeline by viDA Therapeutics Inc, H1 2020
Burns - Pipeline by Washburn Therapeutics Inc, H1 2020
Burns - Dormant Projects, H1 2020
Burns - Dormant Projects, H1 2020 (Contd..1), H1 2020
Burns - Dormant Projects, H1 2020 (Contd..2), H1 2020
Burns - Discontinued Products, H1 2020

List of Figures
Number of Products under Development for Burns, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AlgiPharma AS
  • Alliance Pharma Plc
  • Anterogen Co Ltd
  • Bioharmony Therapeutics Inc
  • Biomendics LLC
  • CFM Pharma Holding BV
  • Chrysalis BioTherapeutics Inc
  • Combangio Inc
  • Destiny Pharma Plc
  • Energenesis Biomedical Co Ltd
  • FirstString Research Inc
  • FortuneRock (China) Ltd
  • GNT Pharma Co Ltd
  • Hunan Sanqing Pharmaceutical Co Ltd
  • Hypo-Stream Ltd
  • Madam Therapeutics BV
  • Mallinckrodt Plc
  • Marizyme Inc
  • MediWound Ltd
  • MicroCures Inc
  • NeoMatrix Therapeutics Inc
  • Novion Technologies Inc
  • Phagelux Inc
  • Riptide Bioscience Inc
  • Se-cure Pharmaceuticals Ltd
  • Shulov Innovative Science Ltd
  • Stemsynergy Therapeutics Inc
  • TGV-Inhalonix Inc
  • Theragnostic Technologies Inc
  • TreeFrog Therapeutics SAS
  • USV Pvt Ltd
  • viDA Therapeutics Inc
  • Washburn Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll